Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arrowhead Research nets $35.4mm through common and preferred stock offering

Executive Summary

With a $9.6mm investment, RA Capital has led a $35.4mm offering by Arrowhead Research Corp. (targeted drug delivery of peptide-drug conjugates and RNAi therapeutics for cancer, obesity, and HBV) of common and convertible preferred stock.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Private Investment in Public Equity
    • Private Placement

Related Companies